Key result
Edoxaban achieved a thrombus disappearance rate of 62.5% in patients with non-acute cancer-associated thrombosis, significantly exceeding the historical control rate of ≤32.0% (p=0.00038).
Why the study?
Cancer-associated thrombosis is a current research focus, and the efficacy of a single-drug approach with edoxaban for non-acute cases required investigation.
Does a single-drug approach with edoxaban improve the thrombus disappearance rate in patients with non-acute cancer-associated thrombosis?
Observational (n=32)
Does a single-drug approach with edoxaban improve the thrombus disappearance rate in patients with non-acute cancer-associated thrombosis?
A single-drug approach with edoxaban is a potential and effective treatment option for resolving non-acute cancer-associated venous thrombosis.
May support edoxaban in non-acute cancer-associated thrombosis; leaves open prospective randomized confirmation.
Recently, cancer-related venous thromboembolism (VTE) has been termed “cancer-associated thrombosis (CAT)” and is the focus of current research. We retrospectively investigated the efficacy of a single-drug approach with edoxaban for the treatment of non-acute CAT. Thirty-two non-acute CAT patients who received edoxaban were analyzed. The primary endpoint of this analysis was the thrombus disappearance rate at the first evaluation. Secondary endpoints included progression/recurrence of VTE, major bleeding, and D-dimer levels. The thrombus disappearance rate was 62.5%. Therefore, the null hypothesis for the primary endpoint (thrombus disappearance rate of ≤32.0%) was rejected (p = 0.00038) based on the rate of the previous study as the historical control. Recurrent VTE and major bleeding occurred in two patients each. After the start of treatment with edoxaban, a significant difference in D-dimer levels was observed (p = 0.00655). We demonstrated that a single-drug approach with edoxaban is a potential treatment option for non-acute CAT.
No takes yet. Share an insight, caveat, or question.
Toshima et al. (2020) conducted an observational in Non-acute cancer-associated venous thrombosis (CAT) (n=32). Edoxaban vs. Historical control was evaluated on Thrombus disappearance rate at the first evaluation (p=0.00038). Edoxaban achieved a thrombus disappearance rate of 62.5% in patients with non-acute cancer-associated thrombosis, significantly exceeding the historical control rate of ≤32.0% (p=0.00038).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: